Adalimumab biosimilar - Fujifilm Kyowa Kirin Biologics

Drug Profile

Adalimumab biosimilar - Fujifilm Kyowa Kirin Biologics

Alternative Names: FKB-327

Latest Information Update: 23 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator FUJIFILM Corporation - Kyowa Hakko Kirin (JV); Fujifilm Kyowa Kirin Biologics
  • Developer Fujifilm Kyowa Kirin Biologics
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Rheumatoid arthritis

Most Recent Events

  • 14 Jun 2017 Efficacy, adverse events, pharmacokinetics and immunogenicity data from a phase III trial in Rheumatoid arthritis presented at the 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
  • 22 May 2017 Preregistration for Rheumatoid arthritis in European Union (SC)
  • 06 Mar 2017 Fujifilm Kyowa Kirin Biologics prepares to file application for marketing authorisation for adalimumab biosimilar
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top